Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.68 USD Market Closed
Market Cap: 75.7m USD

EV/EBITDA
Enterprise Value to EBITDA

0
Current
-4.3
Median
5.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
0
=
Enterprise Value
-2.9m USD
/
EBITDA
-74m USD
EBITDA Growth EV/EBITDA to Growth
US
Aerovate Therapeutics Inc
NASDAQ:AVTE
Average EV/EBITDA: 22.7
0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 156 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
14.8
10%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -481.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
9%
1.4
NL
argenx SE
XBRU:ARGX
88.2
727%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A